Myeloma news from the 2014 annual meeting of the American Society of Clinical Oncology has included updates on proteasome inhibitors, overcoming drug resistance, monoclonal antibodies and more. In this brief video, Dr. James Berenson, a leading myeloma researcher and physician, gives an overview with a focus on what’s important for patients today.
Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief...